Rescued endovascular aneurysm repair using AFX-2 for ruptured, infected iliac aneurysm in disseminated Melioidosis
Article Sidebar
Main Article Content
Abstract
Endovascular aneurysm repair (EVAR) has become a viable alternative to open surgical repair for managing aortoiliac aneurysms, particularly in high-risk patients. Moreover, it is a treatment option for infected aortoiliac aneurysm. Some studies have shown a significantly higher early (30-90 days) mortality rate for EVAR compared with standard open surgical repair.
We reported a case of a 64-year-old male with a concealed ruptured infected iliac aneurysm associated with disseminated melioidosis, successfully treated with endovascular aneurysm repair by an AFX-2 endograft (Endologix, USA) device plus lifelong antibiotics at Phramongkutklao Hospital. The patient demonstrated good early and medium-term results, suggesting that AFX-2 endograft EVAR is a safe and effective option in selected cases. However, a long-term follow-up program is still necessary to monitor long-term efficacy and complications.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles in this journal are copyrighted by the Royal Thai Army Medical Department and published under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
may be read and used for academic purposes, such as teaching, research, or citation, with proper credit given to the author and the journal.
Use or modification of the articles is prohibited without permission.
Statements expressed in the articles are solely the opinions of the authors.
Authors are fully responsible for the content and accuracy of their articles.
Any other republication of the articles requires permission from the journal.
References
Sörelius K, Wanhainen A, Furebring M, Björck M, Gillgren P, Mani K. Nationwide study of the treatment of mycotic abdominal aortic aneurysms comparing open and endovascular repair. Circulation. 2016;134(23):1822–32. doi:10.1161/CIRCULATIONAHA.116.024021
Sörelius K, Budtz-Lilly J, Mani K, Wanhainen A. Systematic review of the management of mycotic aortic aneurysms. Eur J Vasc Endovasc Surg. 2019;58(3):426–35. doi:10.1016/j.ejvs.2019.05.004
Suseela KV, Alex A, Das S. Clinical presentations of melioidosis and antibiogram of Burkholderia pseudomallei: an 8-year study in a tertiary care centre, South India. Int J Adv Med Health Res. 2024;11(1):31–5. doi:10.4103/ijamr.ijamr_123_23
Chakravorty A, Heath CH. Melioidosis: an updated review. Aust J Gen Pract. 2019;48(5):327–32. doi:10.31128/AJGP-04-18-4558
Kaewrakmuk J, Chusri S, Hortiwakul T, Kawila S, Patungkaro W, Jariyapradub B, et al. Under-reporting cases and deaths from melioidosis: a retrospective finding in Songkhla and Phatthalung Province of Southern Thailand, 2014–2020. Trop Med Infect Dis. 2023;8(5):286. doi:10.3390/tropicalmed8050286
Chantratita N, Phunpang R, Yarasai A, Dulsuk A, Yimthin T, Onofrey LA, et al. Characteristics and one-year outcomes of melioidosis patients in northeastern Thailand: a prospective, multicenter cohort study. Lancet Reg Health Southeast Asia. 2023;9:100118. doi:10.1016/j.lansea.2022.100118
Currie BJ, Fisher DA, Howard DM, Burrow JNC, Lo D, Selva-Nayagam S, et al. Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. Clin Infect Dis. 2000;31(4):981–6. doi:10.1086/318116
Boyle R, Withey G, Smith S, Hanson J. Mycotic aneurysms due to Burkholderia pseudomallei in Far North Queensland, tropical Australia: a case series and review of the literature. Acta Trop. 2024;260:107480. doi:10.1016/j.actatropica.2024.107480
Wanhainen A, Van Herzeele I, Bastos Goncalves F, Bellmunt Montoya S, Berard X, Boyle JR, et al. Editor’s Choice – European Society for Vascular Surgery (ESVS) 2024 clinical practice guidelines on the management of abdominal aorto-iliac artery aneurysms. Eur J Vasc Endovasc Surg. 2024;67(2):192–331. doi:10.1016/j.ejvs.2023.11.002
Wyss TR, Giardini M, Sörelius K; Academic Research Consortium of Infective Native Aortic Aneurysm (ARC of INAA). Infective native aortic aneurysm: a Delphi consensus document on treatment, followup, and definition of cure. Eur J Vasc Endovasc Surg. 2024;67(4):654–61. doi:10.1016/j.ejvs.2023.12.008
Shirasu T, Kuno T, Yasuhara J, Yokoyama Y, Takagi H, Cullen MJ, et al. Meta-analysis finds recurrent infection is more common after endovascular than after open repair of infected abdominal aortic aneurysm. J Vasc Surg. 2022;75(1):348–55.e10. doi:10.1016/j.jvs.2021.07.240
Kwolek CJ, Ouriel K, Stucky FS, Rao VK, Pons PJ, Wilson SE, et al. Five-year results of the LEOPARD trial of commercially available endografts. J Vasc Surg. 2023;78(2):324–32.e2. doi:10.1016/j.jvs.2023.04.011
Welborn MB 3rd, McDaniel HB, Johnson RC, Kennedy RE, Knott A, Mundinger GH, et al. Clinical outcome of an extended proximal seal zone with the AFX endovascular aortic aneurysm system. J Vasc Surg. 2014;60(4):876–83; discussion 883–4. doi:10.1016/j.jvs.2014.04.017
Jutidamrongphan W, Kritpracha B, Sörelius K, Hongsakul K, Suwannanon R. Features of infective native aortic aneurysms on computed tomography. Insights Imaging. 2022;13(1):2. doi:10.1186/s13244-021-01135-x
